Anti-tumor necrosis factor-alpha therapy provokes latent leishmaniasis in a patient with rheumatoid arthritis.
It has been reported that anti-tumor necrosis factor-alpha therapy increases the risk of opportunistic infections including rare case reports of leishmaniasis. Here we report a case of latent cutaneous leishmaniasis, which was provoked by anti-tumor necrosis factor-alpha therapy in a patient with rheumatoid arthritis.
Franklin
Gillian
G
Department of Pathology, Long Island Jewish Medical Center, The Long Island Campus of Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA.
Greenspan
Joel
J
Chen
Sheng
S
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D001706:Biopsy; D005260:Female; D006801:Humans; D007891:Leishmania / Q000302:isolation & purification; D016773:Leishmaniasis, Cutaneous / Q000175:diagnosis* / Q000473:pathology; D009297:Nasal Mucosa / Q000469:parasitology / Q000473:pathology; D009666:Nose / Q000473:pathology*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D000981:Antiprotozoal Agents; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000666:Amphotericin B